Hartford Investment Management Co. Sells 265 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Hartford Investment Management Co. decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,640 shares of the medical research company’s stock after selling 265 shares during the period. Hartford Investment Management Co.’s holdings in IQVIA were worth $2,091,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Compound Global Advisors LLC bought a new position in IQVIA during the fourth quarter valued at $334,000. Peterson Wealth Services raised its position in IQVIA by 19.6% during the fourth quarter. Peterson Wealth Services now owns 1,860 shares of the medical research company’s stock valued at $366,000 after purchasing an additional 305 shares during the period. Summit Trail Advisors LLC lifted its stake in shares of IQVIA by 46.3% in the 4th quarter. Summit Trail Advisors LLC now owns 1,855 shares of the medical research company’s stock valued at $365,000 after purchasing an additional 587 shares during the last quarter. Savant Capital LLC purchased a new position in shares of IQVIA in the 4th quarter worth approximately $210,000. Finally, Entropy Technologies LP bought a new position in shares of IQVIA during the 4th quarter valued at approximately $3,624,000. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Down 0.8 %

IQVIA stock opened at $196.18 on Friday. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The business has a fifty day moving average of $200.66 and a two-hundred day moving average of $218.67. The firm has a market cap of $35.61 billion, a P/E ratio of 26.16, a P/E/G ratio of 2.25 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, analysts forecast that IQVIA Holdings Inc. will post 10.81 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IQV has been the subject of several recent analyst reports. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Barclays cut their price target on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Morgan Stanley raised their price objective on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday. The Goldman Sachs Group cut their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, UBS Group decreased their price target on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $251.67.

Insider Buying and Selling

In other news, Director John G. Danhakl purchased 1,275 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were acquired at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.60% of the stock is currently owned by company insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.